BD Licenses Appropriate IP From Cellomics to Support Its Entry Into HCS Marketplace | GenomeWeb

Lending further weight to its intellectual property portfolio, Cellomics announced last week that Becton Dickinson, via its BD Biosciences arm, has licensed Cellomics’ core patents for high-content screening methods.

According to a statement, the agreement provides BD with access to a patent portfolio that includes broad claims to HCS technology, as well as to specific classes of HCS assays such as cytoplasm-nuclear translocation, cellular toxicity characterization, and receptor internalization.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.